UK-based Cobra Biomanufacturing announces an agreement with Pharmexa for the manufacture of the protein vaccine PX107 for use in Phase I clinical trials for bone disorders
The programme will include cell banking, process development and GMP manufacture.
The protein will be manufactured by Cobra, which has earned a global reputation for the manufacturing of therapeutic proteins and vaccines, and has GMP manufacturing facilities in both Keele and Oxford, UK.
The therapeutic vaccine, PX107, makes use of Pharmexa's proprietary active immunotherapy technology, AutoVac.
Currently in preclinical development, PX107 induces a potent polyclonal antibody response towards the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis and bone metastasis with pathological bone destruction.
Pharmexa will be carrying out the upstream and downstream development of PX107 but requires Cobra's cGMP manufacturing capabilities to produce the material for clinical Phase I trials.
David Thatcher, chief executive of Cobra Biomanufacturing, commented: "We very much look forward to providing Pharmexa with our GMP manufacturing expertise to produce their promising vaccine candidate, PX107.
"The product will be manufactured at our Oxford site, which has recently been expanded."
